MiRNA let-7a-5p Ameliorates Pulmonary Fibrosis by Suppressing TGFBR1-Mediated Endothelial-to-Mesenchymal Transition

The lungs are designed to be delicate, a vast network of thin-walled sacs where oxygen slips from the air into the blood. When this system works, it is invisible. But in a condition known as idiopathic pulmonary fibrosis, the lung tissue slowly turns into thick, scar-like material, stiffening the organ until it can no longer breathe. This disease is fatal, and for those who suffer from it, current treatments offer only limited relief. Scientists have long focused on how the cells that line the air sacs break down and how the cells that build scar tissue become overactive. However, a newer line of inquiry suggests that the problem may also begin in the blood vessels. Inside these vessels, there are cells called endothelial cells that normally form a smooth, protective barrier. In this disease, some of these cells appear to lose their identity, shedding their protective nature and transforming into the very cells that create scars. This process, known as endothelial-to-mesenchymal transition, is becoming recognized as a critical step in how the disease takes hold.

Researchers have also been looking at tiny packages called exosomes that travel through the blood. These are small vesicles released by cells that carry messages in the form of genetic material, specifically small molecules known as microRNAs. These molecules act like switches that can turn other genes on or off. The question driving this new study was whether these traveling messages play a role in the transformation of blood vessel cells and the subsequent scarring of the lungs. The team set out to see if a specific microRNA, called let-7a-5p, was missing in patients with the disease and whether restoring it could stop the damage.

The investigation began by looking at the blood of people with idiopathic pulmonary fibrosis and comparing it to the blood of healthy individuals. The researchers found that the levels of let-7a-5p inside the exosomes circulating in the blood were significantly lower in the patients. This drop in levels was not random; it correlated with how severe the disease was in each person. To understand why this mattered, the scientists turned to laboratory experiments using human cells from the lung's blood vessels. They discovered that this specific microRNA has a direct target: a protein on the surface of the cells called TGFBR1. This protein acts as a receiver for a signal that tells cells to change their behavior. The researchers showed that let-7a-5p normally binds to the instructions for making this receiver, effectively stopping the cell from producing too much of it.

When the researchers blocked let-7a-5p in the lab, the cells began to change. They stopped acting like blood vessel cells and started behaving like the scar-forming cells that drive the disease. The cells lost their markers of being blood vessel cells and gained markers of being scar tissue, a shift confirmed by changes in the proteins they produced. Conversely, when the scientists added more of the microRNA back into the cells, the transformation was halted. The cells remained in their healthy state, resisting the signals that usually push them toward becoming scar tissue. This effect was not limited to the blood vessel cells alone. When these cells were placed near lung lining cells, the healthy blood vessel cells, protected by the microRNA, sent signals that helped keep the neighboring lung cells from changing into scar tissue as well.

To see if these findings held true in a living system, the researchers used a mouse model where the lungs were damaged to mimic the human disease. They administered a synthetic version of the microRNA to these mice. The results were clear: the treated mice developed far less scar tissue in their lungs compared to those that did not receive the treatment. Their lungs remained more flexible, and their ability to breathe improved. Detailed analysis showed that the treatment successfully stopped the blood vessel cells from transforming and reduced the activity of the signaling pathway that drives the scarring process.

The study concludes that the low levels of this specific microRNA in the blood are a sign of the disease's progression, suggesting it could serve as a marker to track how the condition is moving forward. More importantly, the work demonstrates that restoring this missing molecule can stop the blood vessel cells from turning into scar-forming cells, thereby slowing the development of fibrosis. While the research points to a potential new way to treat the disease by targeting this specific molecular switch, the findings remain within the scope of the experiments conducted. The study establishes a clear link between the loss of this genetic regulator, the transformation of blood vessel cells, and the stiffening of the lungs, offering a concrete path for understanding how the disease spreads and how it might be stopped.